Germany and Poland are tightening the rules on online prescribing. The ripple effects will reshape medical cannabis access across the continent.
Telemedicine didn’t just support the growth of European medical cannabis—it turbocharged it. Online consultations and e-prescriptions lowered barriers for patients, expanded clinic reach beyond urban centres, and drove a surge in imports across the continent’s largest markets. In Germany, the impact was particularly stark: imports rose 19% in Q3 2025, with telehealth platforms accounting for a significant share of new patient acquisition.
Now, regulators are pushing back. And the consequences could reshape how medical cannabis is prescribed, dispensed and accessed across Europe.
What’s Changing?
Germany’s Bundesrat and federal health authorities are moving to restrict online prescribing and mail-order dispensing of medical cannabis. The concern, broadly stated, centres on clinical oversight—whether remote consultations provide sufficient rigour for prescribing a controlled substance. Poland has already implemented restrictive measures on telehealth prescribing, and other jurisdictions are watching closely. These aren’t peripheral policy adjustments. For the clinics, platforms and pharmacy chains that have built business models around digital-first cannabis prescribing, this represents a fundamental challenge to their operating structure.
The Patient Access Question
The most immediate concern is patient impact. Telehealth expanded access to medical cannabis for patients who couldn’t easily attend in-person consultations—those in rural areas, those with mobility limitations, and those who simply couldn’t take time away from work for a clinic visit. Restricting e-prescriptions doesn’t eliminate demand. It redirects it. Some patients will transition to in-person consultations. Others may turn to unregulated or illicit sources. The net effect on public health outcomes is far from straightforward, and it’s a tension that regulators will need to confront honestly.
Compliance in the New Landscape
For clinics and prescribing platforms, the strategic response needs to be proactive rather than reactive. That means investing in hybrid models that combine digital convenience with clinical robustness, understanding EU cross-border prescription rules, and exploring technology solutions for prescription verification that satisfy regulatory requirements without eliminating patient convenience. Some operators are already pivoting toward models that integrate initial in-person assessments with ongoing telehealth management—a structure that may prove more defensible as regulation tightens.
Cross-Border Implications
Europe’s medical cannabis market doesn’t operate in national silos. German prescribing rules affect Portuguese producers. Polish restrictions influence supply chain planning for distributors across the continent. The telehealth crackdown will create ripple effects through import volumes, pharmacy economics and patient flows that extend well beyond any single jurisdiction. Understanding these cross-border dynamics is essential for anyone operating in or investing in European medical cannabis.
The Advocacy Imperative
The risk of overly restrictive telehealth regulation isn’t theoretical—it’s that patients lose access to lawful medicine. Industry bodies, patient advocacy groups and clinical organisations have a window to engage constructively with regulators, presenting evidence that well-designed telehealth models can maintain clinical standards while preserving access. That conversation needs to happen now, not after legislation is finalised.
Hear the Full Debate at Cannabis Europa
The session on Europe’s telehealth crossroads at Cannabis Europa London on 26–27 May will bring together clinicians, compliance experts, technology providers and policymakers to dissect what’s changing, what it means and what comes next. If telehealth is part of your business model—or your patient journey—this is a session you can’t afford to miss.